The Impact of Low Glycemic Index Nutritional Shake on Glucose Regulation in Overweight and Obese Adults
Launched by ARIZONA STATE UNIVERSITY · Feb 28, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to see how a special nutritional shake, called the SP Glucose-Assist shake, can help manage blood sugar levels in overweight and obese adults. The researchers want to understand if replacing breakfast with this shake will improve glucose regulation compared to a regular oat cereal breakfast. The study will include 40 non-diabetic adults, aged 25 to 65, who have a body mass index (BMI) between 25 and 39.
Participants will start with a week of eating their usual meals, followed by two weeks where they will drink either the shake or eat the oat cereal for breakfast. To be eligible, individuals must have a stable weight, eat three meals a day, and have a BMI within the specified range. However, there are some exclusions, such as having certain health conditions or taking specific medications. This trial will help us learn more about the effects of low glycemic index foods on blood sugar control in everyday life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Body mass index 25-40
- • Eating pattern 3 meals a day
- • stable weight for the last 2 months (\<5 pounds fluctuation)
- • Willing to eat oat cereal for breakfast
- • glycated hemoglobin \<7%
- Exclusion Criteria:
- • glycated hemoglobin \>7%
- • Body mass index ≤25 or ≥ 40
- • Night shifting work
- • Atypical meal pattern (not three meals a day or intermittent fasting)
- • Thyroid medication
- • Bariatric surgery
- • Habitual strenuous exercise
- • Commuting by bicycle
- • Eating disorders
- • Use of aspirin during the duration of the study
- • Intake of Vit C \>60 mg/day during the study
- • cancer
- • cardiovascular disease
- • renal disease
- • hepatic disease
- • X-ray, MRI or CT appointment during the study duration
- • Current infection requiring medication
- • Chronic, contagious, infectious diseases such as tuberculosis, Hepatitis A, B, C, or HIV
- • Medications of supplements that could affect body weight or appetite (i.e. Ozempic)
- • Participating in another study at the same time
About Arizona State University
Arizona State University (ASU) is a leading research institution dedicated to advancing knowledge and innovation in various fields, including health sciences. As a clinical trial sponsor, ASU leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical research aimed at improving patient outcomes and contributing to the scientific community. With a commitment to ethical research practices and collaboration with healthcare professionals, ASU strives to translate research findings into practical applications that benefit society. The university's focus on community engagement and real-world impact underscores its role as a pivotal player in the advancement of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Phoenix, Arizona, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported